A phase II study on metastatic breast cancer patients treated with weekly vinorelbine with or without trastuzumab according to HER2 expression: changing the natural history of HER2-positive diseasePaola Papaldo, F. Cognetti, Isabella Sperduti et al.|Annals of Oncology|2006Cited by 82
Nail disorders in a woman treated with ixabepilone for metastatic breast cancer.Andrea Alimonti, Francesco Cognetti, C. Nardoni et al.|PubMed|2005Cited by 9
Epirubicin plus docetaxel in metastatic breast cancer: escalating dose does not improve efficacy. A phase II study.Alessandra Fabi, F. Cognetti, Paola Papaldo et al.|PubMed|2004Cited by 8
Does the concurrent use of anthracycline and granulocyte colony-stimulating factor influence the risk of secondary leukaemia in breast cancer women?Serena Di Cosimo, Francesco Cognetti, G. Ferretti et al.|Annals of Oncology|2005Cited by 7
Can HER2 overexpression predict response to pegylated liposomal doxorubicin in metastatic breast cancer patients?Alessandra Fabi, F. Cognetti, G. Ferretti et al.|Annals of Oncology|2005Cited by 4